Thrombosis in patients with paroxysmal nocturnal hemoglobinuria

Seminars in Thrombosis and Hemostasis

Volumn 37, Issue 3, 2011, Pages 315-321

  Weitz, Ilene C ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

hemolysis; PNH; thrombosis

Indexed keywords

D DIMER; ECULIZUMAB; FONDAPARINUX; GLYCOSYLPHOSPHATIDYLINOSITOL; HEPARIN; INTERLEUKIN 6; LACTATE DEHYDROGENASE; LOW MOLECULAR WEIGHT HEPARIN; NITRIC OXIDE; PADGEM PROTEIN; PHOSPHATIDYLSERINE; WARFARIN;

ARTERY CONSTRICTION; ARTICLE; BONE MARROW CELL; CELL DIFFERENTIATION; CYTOKINE PRODUCTION; ENDOTHELIUM CELL; ERYTHROCYTE MEMBRANE; GRANULOCYTE; HEMOLYSIS; HEMOSTASIS; HUMAN; HYPERCOAGULABILITY; KIDNEY BLOOD FLOW; LYMPHOCYTE; MONOCYTE; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROPHYLAXIS; PULMONARY HYPERTENSION; RISK FACTOR; THROMBOCYTE; THROMBOSIS;

AGED; ANTICOAGULANTS; GLYCOSYLPHOSPHATIDYLINOSITOLS; HEMOGLOBINURIA, PAROXYSMAL; HUMANS; MIDDLE AGED; THROMBOSIS;

EID: 79953652377     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0031-1273095     Document Type: Article

References (49)

1. Hillmen P, Lewis S M., Bessler M, Luzzatto L, Dacie J V. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1995 333 19 1253-1258
2. Takeda J, Miyata T, Kawagoe K et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell 1993 73 4 703-711 (Pubitemid 23159009)
3. Moyo V M., Mukhina G L., Garrett E S., Brodsky R A. Natural history of paroxysmal nocturnal haemoglobinuria using modern diagnostic assays. Br J Haematol 2004 126 1 133-138 (Pubitemid 38859494)
4. Le X F., Yang T Y., Yang X Y., Wang X M. Characteristics of paroxysmal nocturnal hemoglobinuria in China. Clinical analysis of 476 cases. Chin Med J (Engl) 1990 103 11 885-889
5. Nishimura J, Kanakura Y, Ware R E. et al. Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine (Baltimore) 2004 83 3 193-207 (Pubitemid 38649949)
6. White R H., Keenan C R. Effects of race and ethnicity on the incidence of venous thromboembolism. Thromb Res 2009 123 Suppl 4 S11-S17
7. Rosse W F., Nishimura J. Clinical manifestations of paroxysmal nocturnal hemoglobinuria: present state and future problems. Int J Hematol 2003 77 2 113-120 (Pubitemid 37127562)
8. Hillmen P, Muus P, Dührsen U et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood 2007 110 12 4123-4128 (Pubitemid 350248472)
9. Gostynski M, Engelter S, Papa S, Ajdacic-Gross V, Gutzwiller F, Lyrer P. Incidence of first-ever ischemic stroke in the Canton Basle-City, Switzerland: a population-based study 2002/2003. J Neurol 2006 253 1 86-91 (Pubitemid 43157393)
10. Hill A, Wang X, Sapsford R J., Rother R P., Farrell A L., Jessop H A. et al. Nitric oxide consumption and pulmonary hypertension in patients with paroxysmal nocturnal hemoglobinuria [abstract]. Blood 2006 106 305a
11. Brodsky R A. How I treat paroxysmal nocturnal hemoglobinuria. Blood 2009 113 26 6522-6527
12. Rosse W F., Nishimura J. Clinical manifestations of paroxysmal nocturnal hemoglobinuria: present state and future problems. Int J Hematol 2003 77 2 113-120 (Pubitemid 37127562)
13. Hill A, Reid S A., Rother R P. et al. High definition contrast-enhanced MR imaging in paroxysmal nocturnal hemoglobinuria (PNH) suggests a high frequency of subclinical thrombosis. BJH 2007 137 181-182
14. Dusse L M., Cooper A J., Lwaleed B A. Tissue factor and nitric oxide: a controversial relationship! J Thromb Thrombolysis 2007 23 2 129-133 (Pubitemid 46416858)
15. Omine M, Kinoshita T, Nakakuma H, Maciejewski J P., Parker C J., Socié G. Paroxysmal nocturnal hemoglobinuria. Int J Hematol 2005 82 5 417-421 (Pubitemid 46638691)
16. Rachmilewitz E A., Treves A, Treves A J. Susceptibility of thalassemic red blood cells to phagocytosis by human macrophages in vitro. Ann N Y Acad Sci 1980 344 314-322
17. Connor J, Pak C C., Schroit A J. Exposure of phosphatidylserine in the outer leaflet of human red blood cells. Relationship to cell density, cell age, and clearance by mononuclear cells. J Biol Chem 1994 269 4 2399-2404
18. Hugel B, Socie G, Vu T et al. Elevated levels of circulating microparticles in patients with paroxysmal nocturnal hemoglobinuria and aplastic anemia. Blood 1999 93 10 3451-3456 (Pubitemid 29220912)
19. Parker C J., Omine M, Richards S et al, International PNH Interest Group. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood 2005 106 12 3699-3709 (Pubitemid 41739003)
20. Muus P, Risitano A M., Castro-Malaspina H R., Jones C M., Fuller S, Socie G. Clinical impact of unregulated terminal complement activity in never-transfused patients with paroxysmal nocturnal hemoglobinuria. Blood 2009 114 4029
21. Almeida A M., Murakami Y, Baker A et al. Targeted therapy for inherited GPI deficiency. N Engl J Med 2007 356 16 1641-1647 (Pubitemid 46631673)
22. Meyers G, Parker C J. Management issues in paroxysmal nocturnal hemoglobinuria. Int J Hematol 2003 77 2 125-132 (Pubitemid 37127564)
23. Ritis K, Doumas M, Mastellos D et al. A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J Immunol 2006 177 7 4794-4802 (Pubitemid 44469814)
24. Girardi G, Berman J, Redecha P et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 2003 112 11 1644-1654 (Pubitemid 38063722)
25. Pierangeli S S., Girardi G, Vega-Ostertag M, Liu X, Espinola R G., Salmon J. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum 2005 52 7 2120-2124 (Pubitemid 40994335)
26. Zwicker J I., Liebman H A., Neuberg D et al. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res 2009 15 22 6830-6840
27. Liebman H A., Feinstein D I. Thrombosis in patients with paroxysmal nocturnal hemoglobinuria is associated with markedly elevated plasma levels of leukocyte-derived tissue factor. Thromb Res 2003 111 4-5 235-238 (Pubitemid 38021941)
28. Weitz I, Rochanda L, Liebman H. Effect of eculizumab on thrombocytopenia in patients with paroxysmal nocturnal hemoglobinuria (PNH). Haemotologica June 2009 [abstract]
29. Del Conde I, Bharwani L D., Dietzen D J., Pendurthi U, Thiagarajan P, López J A. Microvesicle-associated tissue factor and Trousseau's syndrome. J Thromb Haemost 2007 5 1 70-74 (Pubitemid 44921069)
30. Louwes H, Vellenga E, de Wolf J TM. Abnormal platelet adhesion on abdominal vessels in asymptomatic patients with paroxysmal nocturnal hemoglobinuria. Ann Hematol 2001 80 10 573-576 (Pubitemid 33061996)
31. Henn V, Slupsky J R., Gräfe M et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998 391 6667 591-594 (Pubitemid 28157601)
32. Wiedmer T, Hall S E., Ortel T L., Kane W H., Rosse W F., Sims P J. Complement-induced vesiculation and exposure of membrane prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria. Blood 1993 82 4 1192-1196 (Pubitemid 23253993)
33. Furie B, Furie B C. P-selectin induction of tissue factor biosynthesis and expression. Haemostasis 1996 26 Suppl 1 60-65 (Pubitemid 26076625)
34. de Latour R P., Mary J Y., Salanoubat C et al, French Society of Hematology French Association of Young Hematologists. Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories. Blood 2008 112 8 3099-3106
35. Weitz I C., Ghods M, Rochanda L, Razavi P, Liebman H. Eculizumab therapy in paroxysmal nocturnal hemoglobinuria results in a rapid and sustained decreases in markers of thrombin generation and inflammation in patients with PNH. Blood 2008 112 407
36. Shi Q, Rafii S, Wu M H. et al. Evidence for circulating bone marrow-derived endothelial cells. Blood 1998 92 2 362-367 (Pubitemid 28323695)
37. Gunsilius E. Bone marrow derived endothelial cells for angiogenesis and antiangiogensis. J Hematother Stem Cell Res 2002 11 153-155 (Pubitemid 34163779)
38. Gao Z, McAlister V C., Williams G M. Repopulation of liver endothelium by bone-marrow-derived cells. Lancet 2001 357 9260 932-933 (Pubitemid 32247285)
39. Sozer S, Fiel M I., Schiano T, Xu M, Mascarenhas J, Hoffman R. The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. Blood 2009 113 21 5246-5249
40. Simak J, Holada K, Risitano A M., Zivny J H., Young N S., Vostal J G. Elevated circulating endothelial membrane microparticles in paroxysmal nocturnal haemoglobinuria. Br J Haematol 2004 125 6 804-813 (Pubitemid 38813608)
41. Helley D, de Latour R P., Porcher R et al. Evaluation of hemostasis and endothelial function in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. Haemotologica 2010 95 574-584
42. Maroney S A., Mast A E. Expression of tissue factor pathway inhibitor by endothelial cells and platelets. Transfus Apheresis Sci 2008 38 1 9-14
43. Ariëns R A., Alberio G, Moia M, Mannucci P M. Low levels of heparin-releasable tissue factor pathway inhibitor in young patients with thrombosis. Thromb Haemost 1999 81 2 203-207 (Pubitemid 29078303)
44. Grünewald M, Siegemund A, Grünewald A et al. Plasmatic coagulation and fibrinolytic system alterations in PNH: relation to clone size. Blood Coagul Fibrinolysis 2003 14 7 685-695 (Pubitemid 37323748)
45. Hall C, Richards S, Hillmen P. Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH). Blood 2003 102 10 3587-3591 (Pubitemid 37409375)
46. Kearon C, Kahn S R., Agnelli G, Goldhaber S, Raskob G E., Comerota A J., American College of Chest Physicians. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008 133 6, Suppl 454S-545S (Pubitemid 351892971)
47. Kuruvilla J, Wells P S., Morrow B, MacKinnon K, Keeney M, Kovacs M J. Prospective assessment of the natural history of positive D-dimer results in persons with acute venous thromboembolism (DVT or PE). Thromb Haemost 2003 89 2 284-287 (Pubitemid 36227280)
48. Hillmen P, Young N S., Schubert J et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006 355 12 1233-1243 (Pubitemid 44427447)
49. Brodsky R A., Young N S., Antonioli E, Risitano A M., Schrezenmeier H, Schubert J et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 2008 111 1840-1847 (Pubitemid 351451491)